CN107428733A - Cd38抑制剂和治疗方法 - Google Patents

Cd38抑制剂和治疗方法 Download PDF

Info

Publication number
CN107428733A
CN107428733A CN201580073761.2A CN201580073761A CN107428733A CN 107428733 A CN107428733 A CN 107428733A CN 201580073761 A CN201580073761 A CN 201580073761A CN 107428733 A CN107428733 A CN 107428733A
Authority
CN
China
Prior art keywords
mmol
cyclohexyl
indole
reaction
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580073761.2A
Other languages
English (en)
Chinese (zh)
Inventor
J.D.贝歇雷尔
R.卡迪拉
D.N.迪顿
C.哈夫纳
B.R.亨克
F.普罗伊沙特
C.舒尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of CN107428733A publication Critical patent/CN107428733A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201580073761.2A 2014-12-03 2015-11-19 Cd38抑制剂和治疗方法 Pending CN107428733A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086844P 2014-12-03 2014-12-03
US62/086844 2014-12-03
PCT/IB2015/058965 WO2016087975A1 (en) 2014-12-03 2015-11-19 Cd38 inhibitors and methods of treatment

Publications (1)

Publication Number Publication Date
CN107428733A true CN107428733A (zh) 2017-12-01

Family

ID=54708091

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580073761.2A Pending CN107428733A (zh) 2014-12-03 2015-11-19 Cd38抑制剂和治疗方法

Country Status (11)

Country Link
US (1) US9840496B2 (https=)
EP (1) EP3227275B1 (https=)
JP (1) JP6550132B2 (https=)
KR (1) KR20170090478A (https=)
CN (1) CN107428733A (https=)
AU (1) AU2015356721B2 (https=)
BR (1) BR112017011642A2 (https=)
CA (1) CA2969178A1 (https=)
ES (1) ES2717260T3 (https=)
RU (1) RU2017121002A (https=)
WO (1) WO2016087975A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115697985A (zh) * 2020-04-07 2023-02-03 米托布里奇公司 Cd38抑制剂
CN116710090A (zh) * 2020-10-09 2023-09-05 Napa医疗有限公司 Cd38的杂芳基酰胺抑制剂
CN119775288A (zh) * 2024-12-31 2025-04-08 浙江工业大学 一种cd38抑制化合物及应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7516047B2 (ja) * 2016-11-23 2024-07-16 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.
MX2022001019A (es) * 2019-07-31 2022-02-22 Ribon Therapeutics Inc Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38).
US20230025807A1 (en) * 2019-10-30 2023-01-26 Mitobridge Inc. Cd38 inhibitors
HRP20251111T1 (hr) 2021-01-29 2025-11-21 Boehringer Ingelheim International Gmbh Azakinolini kao inhibitori cd38
WO2022228496A1 (en) * 2021-04-30 2022-11-03 Nanjing Immunophage Biotech Co., Ltd Compounds and their uses as cd38 inhibitors
TW202310835A (zh) * 2021-07-12 2023-03-16 美商胞質動力學公司 Ｃｄ３８調節劑及其使用方法
WO2024254396A1 (en) * 2023-06-07 2024-12-12 Flagship Pioneering Innovations, Vi, Llc Condensed azines as inhibitors of cyclic adp ribose hydrolase
WO2026000074A1 (en) * 2024-06-25 2026-01-02 Welnx Company Inc. Use of cd38 inhibitors for reducing th2 inflammation
WO2026075971A1 (en) 2024-10-01 2026-04-09 Neolaia Inc. Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059084A2 (en) * 2001-01-04 2002-08-01 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof
WO2003101198A1 (en) * 2002-05-30 2003-12-11 Albert Einstein College Of Medicine Of Zeshiva University Improved inhibitors of adp-ribosyl transferases, cyclases, and hydrolases
WO2014180544A1 (en) * 2013-05-09 2014-11-13 Sanofi Hydantoine derivatives as cd38 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010025235A1 (en) * 2008-08-29 2010-03-04 Regents Of The University Of Michigan Selective ligands for the dopamine 3 (d3) receptor and methods of using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059084A2 (en) * 2001-01-04 2002-08-01 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof
WO2003101198A1 (en) * 2002-05-30 2003-12-11 Albert Einstein College Of Medicine Of Zeshiva University Improved inhibitors of adp-ribosyl transferases, cyclases, and hydrolases
WO2014180544A1 (en) * 2013-05-09 2014-11-13 Sanofi Hydantoine derivatives as cd38 inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115697985A (zh) * 2020-04-07 2023-02-03 米托布里奇公司 Cd38抑制剂
CN116710090A (zh) * 2020-10-09 2023-09-05 Napa医疗有限公司 Cd38的杂芳基酰胺抑制剂
CN119775288A (zh) * 2024-12-31 2025-04-08 浙江工业大学 一种cd38抑制化合物及应用
CN119775288B (zh) * 2024-12-31 2025-10-10 浙江工业大学 一种cd38抑制化合物及应用

Also Published As

Publication number Publication date
RU2017121002A3 (https=) 2019-03-15
RU2017121002A (ru) 2019-01-11
AU2015356721B2 (en) 2018-03-15
US20170260164A1 (en) 2017-09-14
WO2016087975A1 (en) 2016-06-09
JP2018501215A (ja) 2018-01-18
EP3227275A1 (en) 2017-10-11
EP3227275B1 (en) 2019-01-02
ES2717260T3 (es) 2019-06-20
US9840496B2 (en) 2017-12-12
CA2969178A1 (en) 2016-06-09
AU2015356721A1 (en) 2017-06-08
KR20170090478A (ko) 2017-08-07
BR112017011642A2 (pt) 2018-03-06
JP6550132B2 (ja) 2019-07-24

Similar Documents

Publication Publication Date Title
CN107428733A (zh) Cd38抑制剂和治疗方法
EP2603513B1 (en) Heterocyclic compound and use thereof as ampa receptor positive allosteric modulator
EP3286194B1 (en) Imidazotriazinones as pde1 inhibitors
CN102596960B (zh) 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
EP3590940B1 (en) Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
AU2016384921C1 (en) Crystalline form of BTK kinase inhibitor and preparation method thereof
CN105189502B (zh) N‑(4‑(氮杂吲唑‑6‑基)‑苯基)‑磺酰胺及其作为药物的用途
EP2707359A1 (en) Substituted indazole derivatives active as kinase inhibitors
TW200911233A (en) Substituted indazole derivatives active as kinase inhibitors
EA023788B1 (ru) Производные индола и фармацевтические композиции на их основе
EA029644B1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
EA019487B1 (ru) Соединения в качестве ингибиторов plk, фармацевтические композиции, их содержащие, и их применение
EP3068785A1 (en) Substituted 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine derivatives as casein kinase 1 d/e inhibitors
UA105377C2 (uk) Заміщені похідні індазола і азаіндазола як модулятори гамма-секретази
UA80184C2 (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
EP2368876A1 (en) Derivatives of aminoindanes, their preparation and their application in therapeutics
WO2018021977A1 (en) Glycine metabolism modulators and uses thereof
EP1799691B1 (fr) Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CN117486874A (zh) 苯并杂芳环类化合物、其药物组合物及其应用
EP2313376B1 (fr) Derives de 1-benzyl-cinnolin-4-(1h)-one substitues, leur preparation et leur application en therapeutique
CN108341816A (zh) 一种选择性抑制激酶化合物
CN118359542A (zh) 一种多取代的吡唑类化合物及其制备方法和用途
CN108341837A (zh) 一种抑制激酶化合物及其在医学上的用途
JP2020505401A (ja) イミダゾピリダジン化合物
CN117645579A (zh) 作为ripk1抑制剂的氮杂䓬类稠环化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171201